• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The International journal of pharmacy practice >An audit of the prescribing of clopidogrel in the Bebington and West Wirral Primary Care Trust
【24h】

An audit of the prescribing of clopidogrel in the Bebington and West Wirral Primary Care Trust

机译：Bebington and West Wirral初级保健信托基金对氯吡格雷处方的审核

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Clopidogrel is a thienopyridine antiplatelet drug, which decreases platelet aggregation by irreversibly modifying the platelet adenosine diphosphate (ADP) receptor. This is a different mechanism from that of aspirin, allowing the two drugs to be used in combination producing an additive effect.1 Clopidogrel was introduced onto the market in 1998, initially for the prevention of secondary vascular occlusive events only.' Clopidogrel is now licensed for acute coronary syndrome (ACS) without ST-segment elevation in combination with a low-dose of aspirin.1 The current National Institute of Clinical Excellence (NICE) guidelines for ACS are based on the results of the evidence-based trials, CURE and CAPRIE >2 The use of clopidogrel in other indications such as stroke, acute myocardial infarction (MI) and stable angina is currently only as an alternative in aspirin intolerance, however the results from ongoing clinical trials, such as CHARISMA may change this.3 The valid reasons for not taking aspirin according to the Cheshire and Merseyside Cardiac Network (CMCN) guidelines (followed by the primary care trust (PCT)) are, allergy to aspirin, previous gastrointestinal bleed, active or recent peptic ulcer (PU), known or significant aspirin-induced dyspepsia.This study investigates the prescribing patterns of clopidogrel in the Bebington and West Wirral PCT to establish whether or not it is currently following national (NICE and National Service Framework (NSF)) and local guidelines in accordance with best practice.
机译：氯吡格雷是噻吩并吡啶抗血小板药，它通过不可逆地修饰血小板二磷酸腺苷（ADP）受体来减少血小板聚集。这与阿司匹林的作用机制不同，可以将两种药物组合使用产生加和作用。1氯吡格雷于1998年投放市场，最初只是为了预防继发性血管闭塞事件。氯吡格雷现已获得许可，可用于急性冠脉综合征（ACS）且不伴小剂量阿司匹林的ST段抬高。1当前ACS美国国家临床卓越研究所（NICE）指南基于证据试验，CURE和CAPRIE> 2目前，氯吡格雷在中风，急性心肌梗塞（MI）和稳定型心绞痛等其他适应症中的使用仅可替代阿司匹林耐受性，但是正在进行的临床试验（如CHARISMA）的结果可能会改变这是根据柴郡和默西塞德郡心脏网络（CMCN）指南（随后为初级保健基金会（PCT））不服用阿司匹林的正当理由，是对阿司匹林过敏，先前的胃肠道出血，活动性或近期消化性溃疡（PU） ），已知或重要的阿司匹林诱发的消化不良。这项研究调查了Bebington和West Wirral PCT中氯吡格雷的处方模式，以确定目前是否正在随访国家（NICE和国家服务框架（NSF））和当地准则（按照最佳做法）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号